Literature DB >> 3196218

High density lipoprotein cholesterol and mortality. The Framingham Heart Study.

P W Wilson1, R D Abbott, W P Castelli.   

Abstract

In 12 years of follow-up for 2748 Framingham Heart Study participants ages 50 to 79, low levels of high density lipoprotein cholesterol (HDL-C) were associated with increased mortality. For men, the relative risk of death in the first HDL-C quintile (less than 35 mg/dl) as compared to the top quintile (greater than 54 mg/dl) was 1.9 for all causes, and 3.6 and 4.1 for death due to cardiovascular and coronary heart disease (CHD), respectively, after adjustment for standard cardiovascular risk factors. In women, corresponding relative risks, comparing the bottom HDL-C quintile (less than 45 mg/dl) to the top quintile (greater than 69 mg/dl), were 1.5, 1.6, and 3.1. With HDL-C considered as a continuous variable, and after adjustment for standard cardiovascular risk factors, highly significant associations were seen with HDL-C and CHD death in both men and women. In addition, a significant HDL-C effect on total mortality and death due to cardiovascular disease was seen in men. In none of the continuous variable analyses was HDL-C associated with cancer death. We conclude that HDL-C is a potent predictor of CHD death in both sexes and has less consistent associations with other types of death.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3196218     DOI: 10.1161/01.atv.8.6.737

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  134 in total

1.  HDL action on the vascular wall: is the answer NO?

Authors:  Philip W Shaul; Chieko Mineo
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  The heart of the matter of opinion and evidence: the value of evidence-based medicine.

Authors:  Daniel Masvidal; Carl J Lavie
Journal:  Ochsner J       Date:  2012

Review 3.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

4.  CETP inhibitors boost 'good' cholesterol to no avail.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2016-01       Impact factor: 54.908

Review 5.  The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: a meta-analysis of controlled trials.

Authors:  Nele Pattyn; Véronique A Cornelissen; Saeed R Toghi Eshghi; Luc Vanhees
Journal:  Sports Med       Date:  2013-02       Impact factor: 11.136

6.  Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.

Authors:  Katherine P Liao; Jun Liu; Bing Lu; Daniel H Solomon; Seoyoung C Kim
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

7.  Improving mortality prediction using biosocial surveys.

Authors:  Noreen Goldman; Dana A Glei; Yu-Hsuan Lin; Maxine Weinstein
Journal:  Am J Epidemiol       Date:  2009-01-15       Impact factor: 4.897

8.  Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice.

Authors:  Junichiro Tohyama; Jeffrey T Billheimer; Ilia V Fuki; George H Rothblat; Daniel J Rader; John S Millar
Journal:  Atherosclerosis       Date:  2008-09-27       Impact factor: 5.162

9.  High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.

Authors:  Jason Baker; Woubeshet Ayenew; Harrison Quick; Katherine Huppler Hullsiek; Russell Tracy; Keith Henry; Daniel Duprez; James D Neaton
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

10.  Nutrigenomics: a case for the common soil between cardiovascular disease and cancer.

Authors:  Licia Iacoviello; Iolanda Santimone; Maria Carmela Latella; Giovanni de Gaetano; Maria Benedetta Donati
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.